http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2705576-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3353a0515b68520c452bda99c182730 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4035 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-585 |
| filingDate | 2016-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0bd0977c4bb59248f164137051ac5d05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a393636e0e30c24bbf710f4c911f68b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d174ace1dd4bea3de0c85a879e7b7fbe |
| publicationDate | 2019-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2705576-C2 |
| titleOfInvention | Pharmaceutical composition for preventing and/or treating prostate cancer, using benzoheterocyclic compound and method for preventing and/or treating prostate cancer |
| abstract | FIELD: medicine; pharmaceuticals.SUBSTANCE: invention relates to a pharmaceutical composition for preventing and/or treating prostate cancer comprising a therapeutically effective amount of one selected from a group consisting of a benzoheterocyclic compound, presented by formula (I), its pharmaceutically acceptable salt, its stereoisomer, its deuterated compound or its racemate, and a modulator of the androgen receptor signaling pathway. In formula (I), n1 equals 0 or 1; Land Lare independently, CHor; Lis CH; X is NH or O; R, Rand Rare independently H; Z is; where Ris H or D; R, R, R, Rand Rare H; carbon atom denoted by * represents a center of asymmetry; Ris H or; where R', R', R', R' and R' are independently selected from H or substituted (C-C) alkyl; substitute with substituted (C-C) alkyl is morpholinyl; if n1 equals 0, X denotes NH, Lis, CH; and Lisin formula (I), Ris H; if n1 equals 0, X denotes NH, Lis, and Lisin formula (I), Ris H; if n1 equals 1, Lis CH, Lisin formula (I), Ris; D is a deuterium-enriched hydrogen atom and H is a deuterium-poor hydrogen atom; modulator of the androgen receptor signaling pathway is selected from a group consisting of enzalutamide, ARN-509, galterone, ODM-201, abiberone acetate, enzalutamide and gaitherone, enzalutamide and abiraterone acetate, ARN-509 and gaitherone and ARN-509 and abiraterone acetate. Invention also relates to use of a benzoheterocyclic compound represented by formula (I), in preparing a medicinal preparation, to methods for preventing and/or treating prostate cancer.EFFECT: technical result: novel pharmaceutical compositions for preventing and/or treating prostate cancer.17 cl, 11 tbl |
| priorityDate | 2015-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1204.